People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bioniz Therapeutics, Inc. | — | Biotechnology | Series B | $23.6M | $317.5M | 2019 |
Paul E.I. Frohna at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul E.I. Frohna on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ilan Zipkin | 1 | 6 |
| Kleanthis Xanthopoulos | 1 | 4 |
| Joe Kiani | 1 | 3 |
| David Pyott | 1 | 2 |
| Nazli Azimi | 1 | 2 |
| Graham E.I. Cooper | 1 | 1 |
| Michael E.I. Martin | 1 | 1 |
| David E.I. Pyott | 1 | 1 |
| Fredrik E.I. Wiklund | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.